The whole world of gambling is on your smartphone with the Mostbet app - join us!
Home  »  Companies   »  Elevation Oncology Inc. (ELEV) Stock: A Closer Loo...

Elevation Oncology Inc. (ELEV) Stock: A Closer Look at the Market Potential

while the 36-month beta value is 0.33.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

The average price point forecasted by analysts for Elevation Oncology Inc. (ELEV) is $6.50, which is $6.13 above the current market price. The public float for ELEV is 38.53M, and currently, short sellers hold a 3.13% ratio of that floaft. The average trading volume of ELEV on September 15, 2023 was 295.05K shares.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


ELEV) stock’s latest price update

The stock of Elevation Oncology Inc. (NASDAQ: ELEV) has decreased by -4.03 when compared to last closing price of 0.73. Despite this, the company has experienced a -1.92% fall in its stock price over the last five trading sessions. PRNewsWire reported 2023-09-05 that NEW YORK, Sept. 5, 2023 /PRNewswire/ — Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph Ferra, Chief Executive Officer of Elevation Oncology, will present at the H.C.

ELEV’s Market Performance

Elevation Oncology Inc. (ELEV) has seen a -1.92% fall in stock performance for the week, with a -23.16% decline in the past month and a -54.25% plunge in the past quarter. The volatility ratio for the week is 9.24%, and the volatility levels for the past 30 days are at 6.97% for ELEV. The simple moving average for the past 20 days is -8.72% for ELEV’s stock, with a -56.65% simple moving average for the past 200 days.

Analysts’ Opinion of ELEV

Many brokerage firms have already submitted their reports for ELEV stocks, with SVB Securities repeating the rating for ELEV by listing it as a “Outperform.” The predicted price for ELEV in the upcoming period, according to SVB Securities is $8 based on the research report published on May 30, 2023 of the current year 2023.

ELEV Trading at -34.97% from the 50-Day Moving Average

After a stumble in the market that brought ELEV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.12% of loss for the given period.

Volatility was left at 6.97%, however, over the last 30 days, the volatility rate increased by 9.24%, as shares sank -19.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -53.64% lower at present.

During the last 5 trading sessions, ELEV fell by -1.92%, which changed the moving average for the period of 200-days by -30.69% in comparison to the 20-day moving average, which settled at $0.7586. In addition, Elevation Oncology Inc. saw -26.32% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for ELEV

The total capital return value is set at -86.28, while invested capital returns managed to touch -86.77. Equity return is now at value -153.20, with -86.60 for asset returns.

Based on Elevation Oncology Inc. (ELEV), the company’s capital structure generated 60.03 points at debt to equity in total, while total debt to capital is 37.51. Total debt to assets is 31.26, with long-term debt to equity ratio resting at 60.03. Finally, the long-term debt to capital ratio is 37.51.

The liquidity ratio also appears to be rather interesting for investors as it stands at 5.93.


In a nutshell, Elevation Oncology Inc. (ELEV) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Should You Invest in BP p.l.c. (BP) Now?

BP p.l.c. (NYSE: BP) has a higher price-to-earnings ratio of 5.78x compared to its average ratio, and the 36-month beta value for BP is at